Tag Archives: DNA

A Better Way to Make Unnatural Amino Acids Discovered by Yu

Make Unnatural Amino Acids

Certain amino acids that are not found in nature are highly sought after by pharmaceutical manufacturers. These “unnatural” amino acids have traditionally been very difficult to synthesize, so a new and improved technique for doing so is attracting a lot of attention. Amino acids are among the most basic components of living things. Long chains of them, translated from DNA, fold up to become proteins, some smaller groupings of amino acids form hormones, and a Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Patent Parameters


Supreme Court Finds Naturally Occurring DNA to Be Patent Ineligible Last summer, the Supreme Court issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., which concerned the patent eligibility of the BRCA1 and BRCA2 genes. In Myriad, a unanimous Supreme Court held that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated. The Court also determined, albeit with one caveat, that Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

RNAi: From Medicine to Agriculture

Massey copy

At BIO, our member companies are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. They are working everyday to improve the human condition by curing the sick, feeding the hungry, and developing cleaner, safer and healthier sources of energy. And they are accomplishing this by using innovative biotechnology tools, such as RNA interference, or RNAi, in both basic research and product development. RNAi is a biological process, occurring Read More >

Food And Agriculture, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Myriad Supreme Court Decision: BIO’s Statement

4973532326_6c75ba32ba copy

Statement On U.S. Supreme Court Review Of Isolated DNA Patents Washington, D.C. (June 13, 2013) Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO), today issued the following statement on  the U.S. Supreme Court’s decision regarding Myriad Genetics’ patent claims on isolated DNA molecules: “The Supreme Court today summarily ruled that so-called cDNA remains eligible for patenting.  cDNA is the commercially most important form of DNA used in biotechnology.  Today’s decision offers urgently-needed Read More >

Patently BIOtech  |  2 Comments  |  Email This Post
Tags: , , , ,

PTO Genetic Testing Study: What’s Patents Got to Do with It


The USPTO held a hearing on February 16 to collect testimony from interested parties to discuss factors affecting the availability of confirmatory, or second opinion, genetic testing.  However, the hearing quickly devolved into testimonies addressing so called ‘gene patents’ and genetic testing more broadly. Dr. Hans Sauer testified on behalf of BIO and first raised the question whether there is in fact patient demand for an ‘independent second opinion genetic test.’  While doctors would likely Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,